Table 1.
Main features of the enrolled studies
| References | Country | Tumor type | Study design | Number of studies | Age (median) | Dominant ethnicity | Sample | Survival | MicroRNA type |
|---|---|---|---|---|---|---|---|---|---|
| Yokobori et al9 | Japan | Esophageal cancer | R | 108 | 64.9 | Asian | Tissue | OS | miR-23b |
| Dettmer et al14 | Switzerland | Thyroid cancer | R | 26 | NR | Caucasian | Tissue | OS | |
| Ma et al10 | People’s Republic of China | Colorectal cancer | R | 239 | NR | Asian | Tissue | OS | |
| Mraz et al6 | USA | CLL | R | 154 | 56.5 | Caucasian | Tissue | OS | |
| Ciruelos et al8 | USA | Breast cancer | R | 172 | 53.7 | Caucasian | Tissue | OS/PFS | miR-30e, miR-30a, miR-21, miR-210, miR-93, miR-99b, and miR-572 |
| Lee et al11 | Korea | Pancreatic cancer | R | 221 | 60.2 | Asian | Tissue | OS | miR-99a, miR-194, miR-375, miR-342-3p, and miR-487b |
| Lee et al11 | Korea | Pancreatic cancer | R | 189 | NR | Asian | Tissue | OS | miR-99a, miR-194, miR-375, miR-342-3p, and miR-487b |
| Stamatopoulos et al19 | Belgium | CLL | R | 273 | 63 | Caucasian | Cell | OS | |
| Stamatopoulos et al19 | Belgium | CLL | R | 252 | 69 | Caucasian | Serum | OS | |
| Bi et al7 | People’s Republic of China | SCLC | R | 40 | 50 | Asian | Tissue | OS/PFS | |
| Bi et al7 | People’s Republic of China | SCLC | R | 42 | 60.1 | Asian | Tissue | OS/PFS | |
| Fleming et al20 | People’s Republic of China | Melanoma | R | 201 | 61 | Asian | Serum | OS | miR-30d, miR-15b, and miR-425 |
| Fleming et al20 | People’s Republic of China | Melanoma | R | 82 | 59.9 | Asian | Serum | OS | miR-30d, miR-15b, and miR-425 |
Note: Study design is described as P or R.
Abbreviations: CLL, chronic lymphocytic leukemia; NR, not reference; OS, overall survival; P, prospective; PFS, progression-free survival; R, retrospective; SCLC, small-cell lung cancer.